Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 Apr 2024
02 Apr 2024
Historique:
received:
24
05
2023
accepted:
12
03
2024
medline:
3
4
2024
pubmed:
3
4
2024
entrez:
2
4
2024
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a neurodegenerative disease that commonly causes dementia. Identifying biomarkers for the early detection of AD is an emerging need, as brain dysfunction begins two decades before the onset of clinical symptoms. To this end, we reanalyzed untargeted metabolomic mass spectrometry data from 905 patients enrolled in the AD Neuroimaging Initiative (ADNI) cohort using MS-DIAL, with 1,304,633 spectra of 39,108 unique biomolecules. Metabolic profiles of 93 hydrophilic metabolites were determined. Additionally, we integrated targeted lipidomic data (4873 samples from 1524 patients) to explore candidate biomarkers for predicting progressive mild cognitive impairment (pMCI) in patients diagnosed with AD within two years using the baseline metabolome. Patients with lower ergothioneine levels had a 12% higher rate of AD progression with the significance of P = 0.012 (Wald test). Furthermore, an increase in ganglioside (GM3) and decrease in plasmalogen lipids, many of which are associated with apolipoprotein E polymorphism, were confirmed in AD patients, and the higher levels of lysophosphatidylcholine (18:1) and GM3 d18:1/20:0 showed 19% and 17% higher rates of AD progression, respectively (Wald test: P = 3.9 × 10
Identifiants
pubmed: 38565541
doi: 10.1038/s41598-024-56837-1
pii: 10.1038/s41598-024-56837-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6797Subventions
Organisme : Japan Society for the Promotion of Science
ID : 21K18216
Organisme : the National Cancer Center Research and Development Fund
ID : 2020-A-9
Organisme : AMED Japan Program for Infectious Diseases Research and Infrastructure
ID : 21wm0325036h0001
Organisme : JST ERATO Grant
ID : JPMJER2101
Organisme : AMED Brain/MINDS
ID : JP15dm0207001
Organisme : JST National Bioscience Database Center
ID : JPMJND2305
Investigateurs
Michael Weiner
(M)
Paul Aisen
(P)
Ronald Petersen
(R)
Clifford R Jack
(CR)
William Jagust
(W)
John Q Trojanowki
(JQ)
Arthur W Toga
(AW)
Laurel Beckett
(L)
Robert C Green
(RC)
Andrew J Saykin
(AJ)
John Morris
(J)
Leslie M Shaw
(LM)
Enchi Liu
(E)
Tom Montine
(T)
Ronald G Thomas
(RG)
Michael Donohue
(M)
Sarah Walter
(S)
Devon Gessert
(D)
Tamie Sather
(T)
Gus Jiminez
(G)
Danielle Harvey
(D)
Michael Donohue
(M)
Matthew Bernstein
(M)
Nick Fox
(N)
Paul Thompson
(P)
Norbert Schuff
(N)
Charles DeCArli
(C)
Bret Borowski
(B)
Jeff Gunter
(J)
Matt Senjem
(M)
Prashanthi Vemuri
(P)
David Jones
(D)
Kejal Kantarci
(K)
Chad Ward
(C)
Robert A Koeppe
(RA)
Norm Foster
(N)
Eric M Reiman
(EM)
Kewei Chen
(K)
Chet Mathis
(C)
Susan Landau
(S)
Nigel J Cairns
(NJ)
Erin Householder
(E)
Lisa Taylor Reinwald
(LT)
Virginia Lee
(V)
Magdalena Korecka
(M)
Michal Figurski
(M)
Karen Crawford
(K)
Scott Neu
(S)
Tatiana M Foroud
(TM)
Steven Potkin
(S)
Li Shen
(L)
Faber Kelley
(F)
Sungeun Kim
(S)
Kwangsik Nho
(K)
Zaven Kachaturian
(Z)
Richard Frank
(R)
Peter J Snyder
(PJ)
Susan Molchan
(S)
Jeffrey Kaye
(J)
Joseph Quinn
(J)
Betty Lind
(B)
Raina Carter
(R)
Sara Dolen
(S)
Lon S Schneider
(LS)
Sonia Pawluczyk
(S)
Mauricio Beccera
(M)
Liberty Teodoro
(L)
Bryan M Spann
(BM)
James Brewer
(J)
Helen Vanderswag
(H)
Adam Fleisher
(A)
Judith L Heidebrink
(JL)
Joanne L Lord
(JL)
Ronald Petersen
(R)
Sara S Mason
(SS)
Colleen S Albers
(CS)
David Knopman
(D)
Kris Johnson
(K)
Rachelle S Doody
(RS)
Javier Villanueva Meyer
(JV)
Munir Chowdhury
(M)
Susan Rountree
(S)
Mimi Dang
(M)
Yaakov Stern
(Y)
Lawrence S Honig
(LS)
Karen L Bell
(KL)
Beau Ances
(B)
John C Morris
(JC)
Maria Carroll
(M)
Sue Leon
(S)
Erin Householder
(E)
Mark A Mintun
(MA)
Stacy Schneider
(S)
Angela Oliver
(A)
Daniel Marson
(D)
Randall Griffith
(R)
David Clark
(D)
David Geldmacher
(D)
John Brockington
(J)
Erik Roberson
(E)
Hillel Grossman
(H)
Effie Mitsis
(E)
Leyla de Toledo-Morrell
(L)
Raj C Shah
(RC)
Ranjan Duara
(R)
Daniel Varon
(D)
Maria T Greig
(MT)
Peggy Roberts
(P)
Marilyn Albert
(M)
Chiadi Onyike
(C)
Daniel D'Agostino
(D)
Stephanie Kielb
(S)
James E Galvin
(JE)
Dana M Pogorelec
(DM)
Brittany Cerbone
(B)
Christina A Michel
(CA)
Henry Rusinek
(H)
Mony J de Leon
(MJ)
Lidia Glodzik
(L)
Susan De Santi
(S)
P Murali Doraiswamy
(PM)
Jeffrey R Petrella
(JR)
Terence Z Wong
(TZ)
Steven E Arnold
(SE)
Jason H Karlawish
(JH)
David Wolk
(D)
Charles D Smith
(CD)
Greg Jicha
(G)
Peter Hardy
(P)
Partha Sinha
(P)
Elizabeth Oates
(E)
Gary Conrad
(G)
Oscar L Lopez
(OL)
MaryAnn Oakley
(M)
Donna M Simpson
(DM)
Anton P Porsteinsson
(AP)
Bonnie S Goldstein
(BS)
Kim Martin
(K)
Kelly M Makino
(KM)
M Saleem Ismail
(MS)
Connie Brand
(C)
Ruth A Mulnard
(RA)
Gaby Thai
(G)
Catherine Mc Adams Ortiz
(C)
Kyle Womack
(K)
Dana Mathews
(D)
Mary Quiceno
(M)
Ramon Diaz Arrastia
(RD)
Richard King
(R)
Myron Weiner
(M)
Kristen Martin Cook
(KM)
Michael DeVous
(M)
Allan I Levey
(AI)
James J Lah
(JJ)
Janet S Cellar
(JS)
Jeffrey M Burns
(JM)
Heather S Anderson
(HS)
Russell H Swerdlow
(RH)
Liana Apostolova
(L)
Kathleen Tingus
(K)
Ellen Woo
(E)
Daniel H S Silverman
(DHS)
Po H Lu
(PH)
George Bartzokis
(G)
Neill R Graff Radford
(NR)
Francine Parfitt
(F)
Tracy Kendall
(T)
Heather Johnson
(H)
Martin R Farlow
(MR)
Ann Marie Hake
(AM)
Brandy R Matthews
(BR)
Scott Herring
(S)
Cynthia Hunt
(C)
Christopher H van Dyck
(CH)
Richard E Carson
(RE)
Martha G MacAvoy
(MG)
Howard Chertkow
(H)
Howard Bergman
(H)
Chris Hosein
(C)
Sandra Black
(S)
Bojana Stefanovic
(B)
Curtis Caldwell
(C)
Ging Yuek Robin Hsiung
(GYR)
Howard Feldman
(H)
Benita Mudge
(B)
Michele Assaly
(M)
Andrew Kertesz
(A)
John Rogers
(J)
Dick Trost
(D)
Charles Bernick
(C)
Donna Munic
(D)
Diana Kerwin
(D)
Marek Marsel Mesulam
(MM)
Kristine Lipowski
(K)
Chuang Kuo Wu
(CK)
Nancy Johnson
(N)
Carl Sadowsky
(C)
Walter Martinez
(W)
Teresa Villena
(T)
Raymond Scott Turner
(RS)
Kathleen Johnson
(K)
Brigid Reynolds
(B)
Reisa A Sperling
(RA)
Keith A Johnson
(KA)
Gad Marshall
(G)
Meghan Frey
(M)
Jerome Yesavage
(J)
Joy L Taylor
(JL)
Barton Lane
(B)
Allyson Rosen
(A)
Jared Tinklenberg
(J)
Marwan N Sabbagh
(MN)
Christine M Belden
(CM)
Sandra A Jacobson
(SA)
Sherye A Sirrel
(SA)
Neil Kowall
(N)
Ronald Killiany
(R)
Andrew E Budson
(AE)
Alexander Norbash
(A)
Patricia Lynn Johnson
(PL)
Thomas O Obisesan
(TO)
Saba Wolday
(S)
Joanne Allard
(J)
Alan Lerner
(A)
Paula Ogrocki
(P)
Leon Hudson
(L)
Evan Fletcher
(E)
Owen Carmichael
(O)
John Olichney
(J)
Charles DeCarli
(C)
Smita Kittur
(S)
Michael Borrie
(M)
T Y Lee
(TY)
Rob Bartha
(R)
Sterling Johnson
(S)
Sanjay Asthana
(S)
Cynthia M Carlsson
(CM)
Steven G Potkin
(SG)
Adrian Preda
(A)
Dana Nguyen
(D)
Pierre Tariot
(P)
Adam Fleisher
(A)
Stephanie Reeder
(S)
Vernice Bates
(V)
Horacio Capote
(H)
Michelle Rainka
(M)
Douglas W Scharre
(DW)
Maria Kataki
(M)
Anahita Adeli
(A)
Earl A Zimmerman
(EA)
Dzintra Celmins
(D)
Alice D Brown
(AD)
Godfrey D Pearlson
(GD)
Karen Blank
(K)
Karen Anderson
(K)
Robert B Santulli
(RB)
Tamar J Kitzmiller
(TJ)
Eben S Schwartz
(ES)
Kaycee M Sink
(KM)
Jeff D Williamson
(JD)
Pradeep Garg
(P)
Franklin Watkins
(F)
Brian R Ott
(BR)
Henry Querfurth
(H)
Geoffrey Tremont
(G)
Stephen Salloway
(S)
Paul Malloy
(P)
Stephen Correia
(S)
Howard J Rosen
(HJ)
Bruce L Miller
(BL)
Jacobo Mintzer
(J)
Kenneth Spicer
(K)
David Bachman
(D)
Elizabether Finger
(E)
Stephen Pasternak
(S)
Irina Rachinsky
(I)
John Rogers
(J)
Andrew Kertesz
(A)
Dick Drost
(D)
Nunzio Pomara
(N)
Raymundo Hernando
(R)
Antero Sarrael
(A)
Susan K Schultz
(SK)
Laura L Boles Ponto
(LLB)
Hyungsub Shim
(H)
Karen Elizabeth Smith
(KE)
Norman Relkin
(N)
Gloria Chaing
(G)
Lisa Raudin
(L)
Amanda Smith
(A)
Kristin Fargher
(K)
Balebail Ashok Raj
(BA)
Informations de copyright
© 2024. The Author(s).
Références
The Alzheimer’s Association. 2021 Alzheimer’s disease facts and figures. Alzheimers Dement. 17, 327–406 (2021).
doi: 10.1002/alz.12328
Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 367, 795–804 (2012).
doi: 10.1056/NEJMoa1202753
pubmed: 22784036
pmcid: 3474597
Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci. Transl. Med. 6, 226ra30 (2014).
doi: 10.1126/scitranslmed.3007901
pubmed: 24598588
pmcid: 4038930
Brasure, M. et al. Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia: A systematic review. Ann. Intern. Med. 168, 30–38 (2018).
doi: 10.7326/M17-1528
pubmed: 29255839
Fink, H. A. et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: A systematic review. Ann. Intern. Med. 168, 39–51 (2018).
doi: 10.7326/M17-1529
pubmed: 29255847
Manly, J. J. et al. Frequency and course of mild cognitive impairment in a multiethnic community. Ann. Neurol. 63, 494–506 (2008).
doi: 10.1002/ana.21326
pubmed: 18300306
pmcid: 2375143
Knopman, D. S. et al. Alzheimer disease. Nat. Rev. Dis. Primers 7, 33 (2021).
doi: 10.1038/s41572-021-00269-y
pubmed: 33986301
pmcid: 8574196
Blennow, K. et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131–144 (2010).
doi: 10.1038/nrneurol.2010.4
pubmed: 20157306
Iaccarino, L. et al. Diagnostic biomarkers of amyloid and Tau pathology in Alzheimer’s disease: An overview of tests for clinical practice in the United States and Europe. J. Prev. Alzheimer’s Dis. 10, 426–442 (2023).
Jack, C. R., Barrio, J. R. & Kepe, V. Cerebral amyloid PET imaging in Alzheimer’s disease. Acta Neuropathol. 126, 643–657 (2013).
doi: 10.1007/s00401-013-1185-7
pubmed: 24100688
Olsson, B. et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol. 15, 673–684 (2016).
doi: 10.1016/S1474-4422(16)00070-3
pubmed: 27068280
Schindler, S. E. et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, 1647–1659 (2019).
doi: 10.1212/WNL.0000000000008081
Kirmess, K. M. et al. The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin. Chim. Acta 519, 267–275 (2021).
doi: 10.1016/j.cca.2021.05.011
pubmed: 34015303
pmcid: 10292789
Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci. 20, 148–160 (2019).
doi: 10.1038/s41583-019-0132-6
pubmed: 30737462
pmcid: 9382875
Di Paolo, G. & Kim, T. W. Linking lipids to Alzheimer’s disease: Cholesterol and beyond. Nat. Rev. Neurosci. 12, 284–296 (2011).
doi: 10.1038/nrn3012
pubmed: 21448224
pmcid: 3321383
Hamilton, J. A. et al. Brain uptake and utilization of fatty acids, lipids and lipoproteins: Application to neurological disorders. J. Mol. Neurosci. 33, 2–11 (2007).
doi: 10.1007/s12031-007-0060-1
pubmed: 17901539
Cermenati, G. et al. Lipids in the nervous system: From biochemistry and molecular biology to patho-physiology. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 1851, 51–60 (2015).
doi: 10.1016/j.bbalip.2014.08.011
Yin, F. Lipid metabolism and Alzheimer’s disease: Clinical evidence, mechanistic link and therapeutic promise. FEBS J. 290, 1420–1453 (2022).
doi: 10.1111/febs.16344
pubmed: 34997690
pmcid: 9259766
Couttas, T. A. et al. Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer’s disease. Neurobiol. Aging 43, 89–100 (2016).
doi: 10.1016/j.neurobiolaging.2016.03.027
pubmed: 27255818
Matsuzaki, K. Aβ–ganglioside interactions in the pathogenesis of Alzheimer’s disease. Biochim. Biophys. Acta Biomembr. 1862, 183233 (2020).
doi: 10.1016/j.bbamem.2020.183233
pubmed: 32142821
Raulin, A.-C. et al. ApoE in Alzheimer’s disease: Pathophysiology and therapeutic strategies. Mol. Neurodegener. 17, 72 (2022).
doi: 10.1186/s13024-022-00574-4
pubmed: 36348357
pmcid: 9644639
Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. JAMA 278, 1349–1356 (1997).
doi: 10.1001/jama.1997.03550160069041
pubmed: 9343467
Baker-Nigh, A. T. et al. Human central nervous system (CNS) ApoE isoforms are increased by age, differentially altered by amyloidosis, and relative amounts reversed in the CNS compared with plasma. J. Biol. Chem. 30, 27204–27218 (2016).
doi: 10.1074/jbc.M116.721779
St John-Williams, L. et al. Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Sci. Data https://doi.org/10.1038/sdata.2017.140 (2017).
doi: 10.1038/sdata.2017.140
pubmed: 29039849
pmcid: 5644370
Horgusluoglu, E. et al. Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer’s disease. Alzheimer’s Dementia 18, 1260–1278 (2022).
doi: 10.1002/alz.12468
pubmed: 34757660
González Zarzar, T. et al. Sex differences in the metabolome of Alzheimer’s disease progression. Front. Radiol. https://doi.org/10.3389/fradi.2022.782864 (2022).
doi: 10.3389/fradi.2022.782864
pmcid: 9014653
Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat. Genet. 54, 412–436 (2022).
doi: 10.1038/s41588-022-01024-z
pubmed: 35379992
pmcid: 9005347
Meehan, M. et al. Analysis of human serum samples from the Alzheimer’s disease neuroimaging initiative using untargeted metabolomics with LC-MS/MS, Alzheimer’s Dis. Neuroimaging Initiative (2021).
MahmoudianDehkordi, S. et al. Altered bile acid profile associates with cognitive impairment in Alzheimer’s disease—An emerging role for gut microbiome. Alzheimer’s Dementia 15, 76–92 (2019).
doi: 10.1016/j.jalz.2018.07.217
pubmed: 30337151
Teruya, T., Chen, Y. J., Kondoh, H., Fukuji, Y. & Yanagida, M. Whole-blood metabolomics of dementia patientsreveal classes of disease-linked metabolites. Proc. Natl. Acad. Sci. 118, e2022857118 (2021).
doi: 10.1073/pnas.2022857118
pubmed: 34493657
pmcid: 8449400
Wu, L. Y. et al. Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radic. Biol. Med. 177, 201–211 (2021).
doi: 10.1016/j.freeradbiomed.2021.10.019
pubmed: 34673145
Fu, T. T. & Shen, L. Ergothioneine as a natural antioxidant against oxidative stress-related diseases. Front. Pharmacol. 13, 850813 (2022).
doi: 10.3389/fphar.2022.850813
pubmed: 35370675
pmcid: 8971627
Llanoa, D. A. & Devanarayanc, V. Serum phosphatidylethanolamine and lysophosphatidylethanolamine levels differentiate Alzheimer’s disease from controls and predict progression from mild cognitive impairment. J. Alzheimer’s Dis. 80, 311–319 (2021).
doi: 10.3233/JAD-201420
Stephenson, D. T., Lemere, C. A., Selkoe, D. J. & Clemens, J. A. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer’s disease brain. Neurobiol. Dis. 3, 51–63 (1996).
doi: 10.1006/nbdi.1996.0005
pubmed: 9173912
Gattaz, W. F., Maras, A., Cairns, N. J., Levy, R. & Forstl, H. Decreased phospholipase A2 activity in Alzheimer brains. Biol. Psychiatry 37, 13–17 (1995).
doi: 10.1016/0006-3223(94)00123-K
pubmed: 7893853
Chew, H., Solomon, V. A. & Fonteh, A. N. Involvement of lipids in Alzheimer’s disease pathology and potential therapies. Front. Physiol. 11, 539026 (2020).
doi: 10.3389/fphys.2020.00598
Kihara, Y., Maceyka, M., Spiegel, S. & Chun, J. Lysophospholipid receptor nomenclature review: IUPHAR review 8. Br. J. Pharmacol. 171, 3575–3594 (2014).
doi: 10.1111/bph.12678
pubmed: 24602016
pmcid: 4128058
Bai, X. et al. The role of DHCR24 in the pathogenesis of AD: Re-cognition of the relationship between cholesterol and AD pathogenesis. Acta Neuropathol. Commun. 10, 35 (2022).
doi: 10.1186/s40478-022-01338-3
pubmed: 35296367
pmcid: 8925223
Murillo-Rodríguez, E. The role of the CB1 receptor in the regulation of sleep. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32, 1420–1427 (2008).
doi: 10.1016/j.pnpbp.2008.04.008
Farrell, E. K. & Merkler, D. J. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov. Today 13, 558–568 (2008).
doi: 10.1016/j.drudis.2008.02.006
pubmed: 18598910
pmcid: 2667908
Molander-Melin, M. et al. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem. 92, 171–182 (2005).
doi: 10.1111/j.1471-4159.2004.02849.x
pubmed: 15606906